Pfizer’s Five-Year Outlook: Navigating Patent Cliffs and Pipeline Potential

Pfizer's trajectory has shifted dramatically since its pandemic-era peak. The pharmaceutical giant, once buoyed by COVID-19 vaccine sales, now faces a 60% stock decline from late 2021 highs as demand wanes and clinical setbacks mount.

The coming years will test Pfizer's ability to navigate a formidable patent cliff. Key blockbusters—including Eliquis, Prevnar 13, and Ibrance—will lose exclusivity between 2025 and 2027. Even Vyndaqel/Vyndamax, currently protected until 2028 pending extension, adds to the $17 billion revenue at risk.

Pipeline replacements show glimmers of hope. Prevnar 20 already demonstrates the company's strategy of iterative innovation. Yet unanswered questions remain about whether recent acquisitions and internal R&D can fill the impending revenue gap.